Morphle Labs Inc.

A tissue biopsy is a race the patient never sees. Between the moment a sample leaves the body and the moment a pathologist signs a report, the tissue is embedded, sliced thin enough to see through, mounted, stained, and examined under glass. Much of that is still done by hand, and much of it takes three to eight days. Morphle Labs is building the machines that compress it.

Founded in 2017 by IIT Kharagpur robotics engineers Rohit Hiwale and Anchit Navelkar, Morphle Labs makes robotic and AI-driven imaging systems for cancer diagnostics. The premise is blunt: histology is one of the few critical corners of medicine that automation never truly reached. Radiology went digital decades ago. Pathology, by comparison, is roughly one-sixth the size of the digital-radiology market - not because the technology was impossible, but because the scanners were expensive and the software was clumsy.

Morphle attacks both problems at once. Its systems section tissue, scan slides, and move the resulting images into a viewer that a pathologist can open from anywhere. The company describes its approach as "physical AI" - the convergence of intelligent software with high-fidelity hardware, applied to a workflow where a fraction of a micron and a smudge of stain can change a diagnosis.

For years, a competent whole-slide scanner cost upward of $200,000. That is affordable at a research hospital and impossible almost everywhere else. Even where labs could pay, existing scanners often struggled with the messy reality of clinical slides - uneven thickness, variable staining, folds - and the software wrapped around them added friction rather than removing it. The result: pathology stayed analog long after the rest of the diagnostic stack went digital.

Morphle's answer is a lower-cost, robust scanner paired with software that tolerates real-world slide quality and plugs into the lab information system. That combination has drawn two very different kinds of customers. On the research and education side, its MorphoLens scanners are cited in use at Cedars-Sinai, Harvard, the NIH, USC, the University of Miami, and the UK's NHS. On the clinical side, anatomical-pathology and dermatopathology practices - Complete Dermatology, Blue Ocean Derm, Loma Linda Derm among them - use the systems for day-to-day diagnostic reads and remote collaboration.

The through-line is access. A robust scan that a pathologist trusts, delivered at a price a mid-size lab can justify, is what makes telepathology more than a slideshow. "Morphle's tele-pathology setup has huge potential to improve access to diagnostic services," notes one clinician user.

The established names in whole-slide imaging - Leica's Aperio line, Roche's Ventana, Hamamatsu's NanoZoomer, Philips, 3DHistech - built high-end scanners for high-end buyers. Morphle competes on three fronts they largely left open: price, robustness to imperfect slides, and scope.

The scope point is the sharpest. Most vendors sell the scanner and stop at the glass. Morphle also automates the step before it - the microtome. Owning both the robotic sectioning and the scanning means the company is automating a continuous stretch of the workflow rather than a single station. That is a harder engineering problem, which is precisely why Morphle treats it as a moat: 80-plus patents filed across robotics, optics, and imaging, and a product line assembled step by step from 2022 onward.

Morphle sells to labs, cancer hospitals, and research institutes - a B2B model that pairs robotic microtomes and scanners with software for image management, LIS integration, telepathology, and AI analysis. The hardware gets a foot in the lab; the software layer is where the platform thesis lives. The founders have described a future in which the scanner is a foundation others build on - developing disease-detection algorithms and telepathology tools on top of Morphle's rails.

The company reached commercial validation on comparatively little early capital - its founders raised roughly a crore (about $120,000) to a first working product before scaling. In November 2025 it closed a $5 million Series A led by Inflexor Ventures, earmarked for scaling manufacturing of RoboTome and MorphoLens, pursuing international regulatory approvals, and deepening its IP position. Total disclosed funding sits around $6.33 million.